2D DIGE of the cerebrospinal fluid proteome in neurological diseases

Expert Review of Proteomics

Volumn 7, Issue 1, 2010, Pages 29-38

  Tumani, Hayrettin ^a   Lehmensiek, Vera ^a   Lehnert, Stefan ^a   Otto, Markus ^a   Brettschneider, Johannes ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

2D DIGE; Biomarker; Cerebrospinal fluid; Neurological disease; Proteome

Indexed keywords

ACTIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ANGIOTENSINOGEN; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CATHEPSIN D; CERULOPLASMIN; CHROMOGRANIN B; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYSTATIN C; FIBRINOGEN; GELSOLIN; HAPTOGLOBIN; IMMUNOGLOBULIN HEAVY CHAIN; INITIATION FACTOR 4G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEURON SPECIFIC ENOLASE; OSTEOPONTIN; PREALBUMIN; PROCOLLAGEN; PROSTAGLANDIN D SYNTHASE; PROTEIN 14 3 3; PROTEINASE; TRANSFERRIN; VITAMIN D BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; BETA CHAIN; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEMENTIA; GUILLAIN BARRE SYNDROME; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; ISOELECTRIC FOCUSING; MULTIPLE SCLEROSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN VARIANT; PROTEOMICS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL ELECTROPHORESIS; ULTRAFILTRATION;

CEREBROSPINAL FLUID PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; NERVOUS SYSTEM DISEASES; PROTEOME; PROTEOMICS;

EID: 77951643449     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.09.99     Document Type: Review

References (52)

1. Biomarkers and surrogate endpoints: preferred defnitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
2. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 127(Pt 7), 1463-1478 (2004).
3. Prentice RL. Surrogate endpoints in clinical trials: defnition and operational criteria. Stat. Med. 8(4), 431-440 (1989).
4. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. (1), CD001447 (2007).
5. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. (1), CD005593 (2006).
6. Tumani H, Teunissen C, Sussmuth S, Otto M, Ludolph AC, Brettschneider J. Cerebrospinal fuid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev. Mol. Diagn. 8(4), 479-494 (2008).
7. Reiber H. Flow rate of cerebrospinal fuid (CSF)-a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci. 122(2), 189-203 (1994).
8. Lehmensiek V, Sussmuth SD, Brettschneider J et al. Proteome analysis of cerebrospinal fuid in Guillain-Barré syndrome (GBS). J. Neuroimmunol. 185(1-2), 190-194 (2007).
9. Lehmensiek V, Sussmuth SD, Tauscher G et al. Cerebrospinal fuid proteome profle in multiple sclerosis. Mult. Scler. 13(7), 840-849 (2007).
10. Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand. 88(3), 221-223 (1993).
11. Teunissen CE, Scheltens P. Use of proteomic approaches to identify disease biomarkers. Lancet Neurol. 6(12), 1036-1037 (2007).
12. Freeman WM, Hemby SE. Proteomics for protein expression profling in neuroscience. Neurochem. Res. 29(6), 1065-1081 (2004).
13. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fuorescence difference gel analysis technology. Anal. Bioanal. Chem. 382(3), 669-678 (2005).
14. Unlü M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18(11), 2071-2077 (1997).
15. Davidsson P, Sjogren M. Proteome studies of CSF in AD patients. Mech. Ageing Dev. 127(2), 133-137 (2006).
16. Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM. Comparative proteomic analysis of intra-and interindividual variation in human cerebrospinal fuid. Mol. Cell. Proteomics 4(12), 2000-2009 (2005).
17. Huang JT, Wang L, Prabakaran S et al. Independent protein-profling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol. Psychiatry 13(12), 1118-1128 (2008).
18. Huang JT, Leweke FM, Tsang TM et al. CSF metabolic and proteomic profles in patients prodromal for psychosis. PLoS ONE 2(1), e756 (2007).
19. Widl K, Brettschneider J, Schattauer D et al. Erythropoietin in cerebrospinal fuid: age-related reference values and relevance in neurological disease. Neurochem. Res. 32(7), 1163-1168 (2007).
20. Yuan X, Desiderio DM. Proteomics analysis of human cerebrospinal fuid. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 815(1-2), 179-189 (2005).
21. Davidsson P, Folkesson S, Christiansson M et al. Identifcation of proteins in human cerebrospinal fuid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun. Mass Spectrom. 16(22), 2083-2088 (2002).
22. Yuan X, Desiderio DM. Proteomics analysis of prefractionated human lumbar cerebrospinal fuid. Proteomics 5(2), 541-550 (2005).
23. Lilley KS, Friedman DB. All about DIGE: quantifcation technology for differential-display 2D-gel proteomics. Expert Rev. Proteomics 1(4), 401-409 (2004).
24. Brettschneider J, Mogel H, Lehmensiek V et al. Proteome analysis of cerebrospinal fuid in amyotrophic lateral sclerosis (ALS). Neurochem. Res. 33(11), 2358-2363 (2008).
25. Brechlin P, Jahn O, Steinacker P et al. Cerebrospinal fuid-optimized two-dimensional difference gel electrophoresis (2D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 8(20), 4357-4366 (2008).
26. Gharbi S, Gaffney P, Yang A et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol. Cell. Proteomics 1(2), 91-98 (2002).
27. Becker JS, Jakubowski N. The synergy of elemental and biomolecular mass spectrometry: new analytical strategies in life sciences. Chem. Soc. Rev. 38(7), 1969-1983 (2009).
28. Hillenkamp F, Karas M, Beavis RC, Chait BT. Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. Anal. Chem. 63(24), A1193-A1203 (1991).
29. Cottrell JS. Protein identifcation by peptide mass fngerprinting. Pept. Res. 7(3), 115-124 (1994).
30. Steen H, Mann M. The ABC's (and XYZ's) of peptide sequencing. Nat. Rev. Mol. Cell Biol. 5(9), 699-711 (2004).
31. Rohrbough JG, Galgiani JN, Wysocki VH. The application of proteomic techniques to fungal protein identifcation and quantifcation. Ann. NY Acad. Sci. 1111, 133-146 (2007).
32. Ahmed FE. Utility of mass spectrometry for proteome analysis: part I. Conceptual and experimental approaches. Expert Rev. Proteomics 5(6), 841-864 (2008).
33. Ahmed FE. Utility of mass spectrometry for proteome analysis: part II. Ion-activation methods, statistics, bioinformatics and annotation. Expert Rev. Proteomics 6(2), 171-197 (2009).
34. Carrette O, Demalte I, Scherl A et al. A panel of cerebrospinal fuid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3(8), 1486-1494 (2003).
35. Andreasen N, Vanmechelen E, Van de Voorde A et al. Cerebrospinal fuid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J. Neurol. Neurosurg. Psychiatry 64(3), 298-305 (1998).
36. Ray S, Britschgi M, Herbert C et al. Classifcation and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13(11), 1359-1362 (2007).
37. Brettschneider J, Claus A, Kassubek J, Tumani H. Isolated blood-cerebrospinal fuid barrier dysfunction: prevalence and associated diseases. J. Neurol. 252(9), 1067-1073 (2005).
38. Bossuyt PM, Reitsma JB, Bruns DE et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin. Chem. 49(1), 7-18 (2003).
39. Brazma A, Hingamp P, Quackenbush J et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29(4), 365-371 (2001).
40. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer 93(4), 387-391 (2005). (Pubitemid 43080010)
41. Wilkins MR, Appel RD, Van Eyk JE et al. Guidelines for the next 10 years of proteomics. Proteomics 6(1), 4-8 (2006).
42. Taylor CF, Paton N W, Lilley KS et al. The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol. 25(8), 887-893 (2007).
43. Tonge R, Shaw J, Middleton B et al. Validation and development of fuorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 1(3), 377-396 (2001).
44. Rozek W, Ricardo-Dukelow M, Holloway S et al. Cerebrospinal fuid proteomic profling of HIV-1-infected patients with cognitive impairment. J. Proteome Res. 6(11), 4189-4199 (2007).
45. Gao WM, Chadha MS, Berger RP et al. A gel-based proteomic comparison of human cerebrospinal fuid between inficted and non-inficted pediatric traumatic brain injury. J. Neurotrauma 24(1), 43-53 (2007).
46. Jin T, Hu LS, Chang M, Wu J, Winblad B, Zhu J. Proteomic identifcation of potential protein markers in cerebrospinal fuid of GBS patients. Eur. J. Neurol. 14(5), 563-568 (2007).
47. Qin Z, Qin Y, Liu S. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell. Mol. Neurobiol. 29(2), 203-210 (2009).
48. Liu S, Bai S, Qin Z, Yang Y, Cui Y, Qin Y. Quantitative proteomic analysis of the cerebrospinal fuid of patients with multiple sclerosis. J. Cell. Mol. Med. 13(8A), 1586-1603 (2009).
49. Tian XJ, Li JY, Huang Y, Xue Y P. Preliminary analysis of cerebrospinal fuid proteome in patients with neurocysticercosis. Chin. Med. J. (Engl.) 122(9), 1003-1008 (2009).
50. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand. J. Clin. Lab. Invest. 37(5), 397-401 (1977).
51. Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fuid barrier and the quantitation of the humoral immune response within the central nervous system. Clin. Chim. Acta. 163(3), 319-328 (1987).
52. Reiber H, Peter JB. Cerebrospinal fuid analysis: disease-related data patterns and evaluation programs. J. Neurol. Sci. 184(2), 101-122 (2001).